Iowa Cannabis Market Analysis: $13.7M Medical, ~$760M Outside the Program, 1.8% Capture

Iowans spend an estimated three-quarters of a billion dollars a year on cannabis. About $13.7 million of it — 1.8% — passes through the state's five licensed dispensaries. The rest, roughly $760 million annually — about $2.1 million every day — is spending Iowa's medical channel never touches. No jurisdiction in this dataset performs worse, and it is not close: the median medical-only program captures roughly nine times Iowa's share. Iowa's program is not underperforming its structure. The structure is the performance.

The Headline Math

The framework's standard demand model: U.S. Census Bureau estimates put Iowa's 21-and-over population at approximately 2.36 million. At the 18% participation baseline, that is roughly 425,000 cannabis consumers. At 1.0 gram per day, resident demand is approximately 155 million grams annually.

Priced at $5.00 per gram — a conservative blended figure below what most legal markets charge and consistent with regional informal-market pricing — total resident spending is approximately $775 million per year.

Legal medical sales, per the Medical Cannabidiol Board's 2025 Annual Report to the Iowa General Assembly, were $13.75 million for the twelve months ending October 2025.

The remainder — approximately $760 million — is demand served outside Iowa's medical program. Some of it is illicit supply, untaxed and untested. Some is informal sharing and home cultivation. Some flows through Iowa's regulated consumable hemp market. And some of it is purchased legally in Illinois, Minnesota, and Missouri — tax revenue collected by other states from Iowa residents, even though transporting it home remains unlawful. The model cannot split the remainder among those channels, and doesn't need to: whatever the mix, Iowa's licensed medical market serves 1.8% of modeled demand and the other 98.2% found somewhere else to go.

Every figure in that calculation except the sales number is a framework input rather than an observed measure; move the price to $4 or the participation rate to 15% and the outside-the-program figure lands between $500 million and $800 million. There is no defensible set of inputs under which it is not several hundred million dollars, and no set under which legal capture exceeds low single digits.

No Program Performs Worse

Medical-only structure is not the explanation. Medical-only programs across this dataset routinely capture 15–35% of modeled demand:

Capture figures are modeled estimates from their respective analyses using identical framework inputs.

Read down that column and consider what each row required. Pennsylvania reaches 35% with an annual physician visit and a $50 card fee — a medical program serving roughly one in four of the state's cannabis consumers. Mississippi — a state with no shortage of cultural resistance to cannabis — hit 16% in its third year of operation. West Virginia manages 15% in one of the poorest states in the country. Hawaii captures 11% on isolated islands at $9.20 per gram with 25 stores.

Iowa is finishing its seventh full year of sales at 1.8%.

Utah is the sharpest comparison. Utah's adult 21+ population is nearly identical to Iowa's, its political culture at least as conservative, and its resident participation plausibly runs below the 18% baseline given the size of its abstaining religious population — an inference, not a measurement, but a conservative one for this comparison. Utah's medical program still generates $183 million annualized through 15 dispensaries and 113,202 active cardholders — roughly thirteen times Iowa's revenue and six times its patient count from a comparably sized population. Whatever discount Iowa's culture warrants, Utah has already priced it in and still outsells Iowa 13-to-1.

What $13.7M Buys

The program's own report describes a market that has stopped moving:

• Active patients: 18,230 (2023) → 17,999 (2024) → 18,012 (2025)
• Annual sales: $13.61M → $12.99M → $13.75M
• New certifying practitioners: 512 in 2019, 308 in 2020, and just 97 in 2025 — about eight per month statewide
• Total card approvals (new plus renewals) declined from 18,283 to 16,714 over two years
• 75 total industry jobs across two manufacturers and five dispensaries

Per-patient spending is approximately $760 per year — about $63 per month. Mississippi's patients average roughly $175 per month; Arkansas's roughly $210. Iowa's patients spend a third of what comparable medical patients spend, and the reasons are structural, not behavioral.

Three Structural Ceilings

No flower, in any channel. Iowa Code chapter 124E permits extracts — and 78% of program sales are inhaled products, 90.9% high-THC formulation — but prohibits cannabis flower entirely, a prohibition the Board reaffirmed unanimously on November 14, 2025. Meanwhile Iowa's consumable hemp framework legalizes 4mg-per-serving THC gummies for adults 21 and older, while Iowa Code §204.14A makes inhaling a hemp product a serious misdemeanor; raw hemp may circulate only as an agricultural commodity labeled not for human consumption. The result: a cardholder can buy a high-THC distillate cartridge, any adult can buy a low-dose edible, and no one in Iowa can legally buy dried cannabis or hemp flower for human inhalation at any potency. Flower remains the largest single product category even in the most mature legal markets — in Oregon, nine years in and after a sustained consumer shift toward vapes and concentrates, flower still accounts for 42% of revenue per OLCC category data. Iowa has banned the largest product category in cannabis from both of its legal channels and priced the consequences into that 1.8%.

A default THC cap set at a quarter of the model's consumption baseline. The purchase limit — 4.5 grams of THC per 90 days — works out to 50 milligrams of THC content per day. The framework's baseline, 1.0 gram of flower daily at roughly 20% potency, contains about 200 milligrams. The state's own waiver data strongly suggests the default cap binds: roughly 27% of active patients hold a provider-signed waiver to exceed it — a share that climbed from 1.3% in 2020 to about 27% by 2024 and has held near that level — and a third of waiver recipients participated for more than a year before obtaining one. If every active patient used the full default allotment, the program would dispense roughly 329 kilograms of THC annually against modeled statewide demand of roughly 31,000 kilograms — about 1.1%. Waivers raise the true ceiling, but their prevalence demonstrates how restrictive the default is.

Five stores for 2.36 million adults. That is 0.21 dispensaries per 100,000 adults — the sparsest footprint in this dataset by a factor of three (Utah, the next sparsest, has 0.65). The Board's report states plainly that many patients travel two or more hours. There is no dispensary in Des Moines proper, none in Cedar Rapids or Davenport, and all five locations sit on or north of the Interstate 80 corridor — the southern third of the state has none. Three of Iowa's six neighbors — Illinois, Minnesota, Missouri — operate adult-use markets. For some border-region Iowans, the nearest licensed cannabis retailer may well be in another state.

The Board's Report Indicts the Program It Defends

The remarkable thing about the 2025 annual report is that the Board's own recommendations concede nearly every point above. It asks the legislature for more dispensary licenses based on demand analysis, a sales tax exemption for patients, decoupling from federal 280E, and a program name that reflects what it actually sells. Each recommendation identifies a structural constraint. And the same document eases none of the two that matter most: the flower prohibition — unanimously re-ratified — and the default THC cap, left untouched.

The reaffirmation of the flower ban rests on a subcommittee review, attached as Appendix A, whose stated methodology was a PubMed search plus a query to "an artificial intelligence large language model (LLM), specifically ChatGPT5o." The appendix's own annotations list five placebo-controlled randomized trials of vaporized flower and summarize them in the report's own words — "significant analgesia vs placebo" (Wilsey 2013), "dose-dependent reduction in spontaneous and evoked pain" (Wallace 2015), "significant analgesic response" (Wilsey 2016), and a 2024 migraine RCT "superior to placebo at 2 h for pain relief, pain freedom, and most-bothersome-symptom freedom... no serious AEs" (Schuster 2024). The conclusion states that evidence supporting vaporized flower "cannot be found." The conclusion and the contradictory trial summaries appear on consecutive pages. Readers can measure the distance themselves.

The subcommittee's grounds for discounting the trials are methodological — small samples, short durations, self-titrated dosing — which are the standard limitations of research conducted under Schedule I. Notably, the report does not apply the same explicit trial-evidence standard to the high-THC vapor products the program already permits. The evidence bar exists for flower and only for flower.

The Bottom Line

Iowa's medical program is stable, compliant, professionally run — and irrelevant to roughly 98% of the market it nominally addresses. Approximately $760 million a year in Iowa cannabis demand is served everywhere except the state's licensed medical channel: by illicit supply the state neither taxes nor tests, by tax revenue exported to dispensaries in Illinois, Minnesota, and Missouri, and by a hemp market serving demand the medical program won't. Meanwhile the legal channel collects about $14 million serving roughly 4% of the state's estimated consumers. The program's oversight board has documented every binding constraint in its own annual report and recommended easing several — access, licensing, taxes — while leaving the flower prohibition and the default THC cap intact.

The April 2026 final rule makes the failure more expensive. Marijuana covered by qualifying state medical licenses now receives Schedule III treatment, and qualifying licensees are no longer subject to 280E — while adult-use marijuana remains Schedule I. Iowa's medical-only structure extends that federal tax advantage across its entire licensed market; neighboring dual-market states receive it only for their qualifying medical operations. Iowa holds one of the most federally advantaged program structures in its region and converts it into the lowest capture rate in this dataset. Seven years of flat data say the program has found its equilibrium. The other $760 million found one too.

This analysis applies the Dan K Reports Cannabis Market Framework. For methodology, assumptions, and the complete state-by-state comparison, see the framework documentation.